Systemic immune response after mucosal immunization in patients with IgA nephropathy.
Increased IgA production has been proposed as a portion of the etiology of IgA nephropathy. Indirect human data suggest that IgG and complement may be equally important. We have immunized 17 patients with IgA nephropathy and 27 controls with tetanus toxoid. They were nasally immunized and, 2 weeks later, received an im booster immunization. This protocol has been shown to result in an increased serum IgA1 antibody response to tetanus toxin (TT). Patients had higher serum IgG antibodies to TT before and after the im immunization than did controls (pre, 42 vs 13 U; post, 155 vs 71 U; P = 0.004). Patients also had a greater increase in serum IgG antibodies (118 vs 58; P = 0.02). After the im TT, patients had lower levels of serum IgA1 antibody to TT (115 vs 180; P = 0.005) but the change in IgA1 antibodies was not significant. These data suggest that patients with IgA nephropathy may produce inappropriately large amounts of serum IgG antibodies to antigens encountered in the upper respiratory tree. Such antigens also induce a serum IgA1 response. Such a response could result in the formation of potentially nephritogenic immune complexes containing IgG, IgA1, and C3.
Waldo
F B
FB
Department of Pediatrics, University of Alabama, Birmingham.
D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000917:Antibody Formation; D002648:Child; D004797:Enzyme-Linked Immunosorbent Assay; D005922:Glomerulonephritis, IGA / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D007117:Immunization, Secondary; D007070:Immunoglobulin A / Q000096:biosynthesis; D007074:Immunoglobulin G / Q000096:biosynthesis; D007273:Injections, Intramuscular; D008875:Middle Aged; D012044:Regression Analysis; D013744:Tetanus Toxin / Q000494:pharmacology* / Q000627:therapeutic use; D014611:Vaccination
D007070:Immunoglobulin A; D007074:Immunoglobulin G; D013744:Tetanus Toxin